Introduction
Many neurodegenerative diseases are characterised by abnormal post-translational modification (PTM) of one or more proteins leading to their aggregation and, by mechanisms not yet fully understood, ultimately to neuronal cell death. One of the most common forms of pathological PTM is phosphorylation, with phosphorylated forms of tau (AD), TDP-43 (ALS, FTLD) and alphasynuclein (PD) all associated with disease, whereas decreased phosphorylation on huntingtin (HD) is thought to be protective. The role of cell signalling pathways, mostly regulated by kinase/phosphatase cascades is also increasingly being recognised as modulating key aspects of neurodegeneration such as re-activation of cell cycle in neuronal cells and activation of immune cells such as microglia and astrocytes. Accordingly, there is a strong rationale to develop and apply global phosphorylation profiling to neuronal cell cultures and brain tissues used in neurodegenerative disease research. We have recently reported SysQuant, a global phosphoproteomic workflow that employs isobaric Tandem Mass Tags (TMT) and differential chromatography to measure fractions of both enriched phosphopeptides and the un-enriched non-phosphorylated peptides derived from tryptic digestion of tumour cell lysates of up to 10 samples in a single mass spectrometry experiment (1) .
We have now applied SysQuant to frozen brain tissue from a mouse model of human tauopathy (TMHT Mouse, QPS Austria) treated with vehicle or vehicle + kinase inhibitors, and we are able to demonstrate significant, potentially protective effects on the phosphorylation of aggregating proteins, as well as regulation of key pathways such as glycolysis/gluconeogenesis, calcium signalling, oxidative phosphorylation, citrate cycle along with all major neurodegenerative KEGG pathways. By using a TMT 10plex labelling strategy we were able to generate a detailed, quantitative phosphoproteomic map for 3 x 3 x 3 animals treated with vehicle or one of two kinase inhibitors from hippocampus, cortex and rest of brain regions in approximately 8 weeks. Data from the hippocampus is presented here.
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Bioinformatic Processing
Raw mass spectrometry data were searched against the human UniProtKB/Swiss-Prot database using Mascot and Sequest (Proteome Discoverer, Thermo Scientific). A 5% FDR filter was used to reject matches with low confidence scores. The identified peptide and protein numbers can be seen in table 1. High-confidence phosphopeptides (≥75% phospho-RS probability score) were considered for further analysis. Quantifiable peptides represent those which had a signal in all TMT10plex channels. Sum-scaling was used to normalise the intensity values of the 10 isobaric tags to reduce any bias prior to quantitation. Log2 ratio's of the average signal intensity across the TMT channels corresponding to each treatment group (n=3 per group) were calculated and used to highlight differential regulation between vehicle-and kinase inhibitor treated groups at the peptide and protein level. The significance of the log2 ratio was determined by a 2-sample t-test, with significance set at p ≤ 0.05.
Results
Utilising the log2 ratio we can identify peptides and phosphopeptides that are modulated with kinase inhibitor treatment. The dataset of almost 100,000 peptides can be mined for any protein of interest, known down-stream targets of compound treatment, or for specific phosphorylation site changes, as well as for unbiased searching for non-canonical signalling events. The TMHT mouse model is known to overexpress a mutated human tau transgene and is considered a model for tauopathies, including AD. We can therefore focus our initial data analysis on tau and proteins implicated in AD.
In our dataset we detected 124 unique tau peptides, corresponding to 88% coverage of the human tau sequence (Figure 2) . Singly, doubly and mulitply phosphorylated tau peptides were detected, and in total 39 different phosphosites within the sequence were observed.
. The role of tau hyperphosphorylation in AD is well-documented. Regulation of a number of tau phosphosites was detected in the samples from mice treated with the kinase inhibitors. The graphs in Figure 3 show examples of the down-regulated phosphopeptides seen with treatment Applying the SysQuant workflow to brain tissue has allowed us to identify many AD-related proteins of interest (Table 2) . We have good coverage of these proteins, and in almost all cases we see evidence of phosphorylation. SysQuant has also allowed identification of proteins key to the pathology of other neurodegenerative disorders. TDP-43 is highly implicated in ALS and FTLD, with hyperphosphorylation resulting in protein aggregation. In our dataset we detect 20 unique TDP-43 peptides, resulting in 48% coverage of the protein sequence ( Figure 4A ). Similarly, aggregation of alpha-synuclein is well documented in PD. We detect 17 peptides from the alpha-synuclein, relating to 93% of the sequence ( Figure 4B ).
Protein
Detected by SysQuant Coverage Phosphopeptides Seen The SysQuant output can also be used for data-driven analysis, and the inclusion of KEGG pathway information in the processed dataset allows the effects of drug treatments or differences between control and disease for example, to be examined on a system wide level.
We mapped the protein accession numbers from our dataset to the associated KEGG pathways. 22 different KEGG pathways were shown to be significantly regulated with kinase inhibitor treatment including the neurodegenerative disease pathways, TCA cycle, oxidative phosphorylation ( Figure 5A ) and calcium signaling ( Figure 5B ). Using the log2 ratio values we were able to colour code the KEGG maps to highlight which of the proteins were up-regulated, down-regulated or un-affected with treatment. Figure 6 shows the AD coloured KEGG pathway as an example. 
Conclusions
• SysQuant with TMT10plex can be applied to brain tissue to achieve global quantitative proteomic profiling in multiple samples in a single experiment yielding 100,000 peptide IDs and over 22,000 phosphosites.
• Mapping protein IDs to KEGG pathways allows the system-wide effect of treatment to be determined.
• Inhibition of casein kinase 1 delta/epsilon has multiple effects consistent with a positive therapeutic effect in tauopathies.
